This pilot clinical trial studies how well social media listening works in improving clinical trial recruitment in patients with cancer. Social media listening and recruitment on Twitter may enhance enrollment for cancer-related clinical trials.
PRIMARY OBJECTIVES: I. Examine the feasibility (acceptance among University of Southern California \[USC\] Norris study team members and Twitter users in Los Angeles \[LA\] county) of targeted social media listening (SML) via Twitter as a tool for enhancing recruitment to cancer trials. II. Gain preliminary data on the impact (i.e., numbers recruited versus projected accrual compared to historic recruitment) of targeted social media listening (SML) as a tool for enhancing recruitment to cancer trials among Twitter users in LA county. III. Estimate the effect size of the number of people enrolled associated with the use of targeted social media listening (SML) via Twitter as a tool for enhancing recruitment to cancer trials. OUTLINE: Patients who mention specific cancer disease keywords and/or hashtags are identified and receive a message via Twitter. Patients are then contacted for recruitment into a clinical trial.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE
Receive message via Twitter
Ancillary studies
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
User acceptance and satisfaction with social media (SM) as a recruitment method
A questionnaire will be used assess the acceptance of and satisfaction with SM recruitment method among University of Southern California (USC) Norris study team members and Twitter users in Los Angeles (LA) county.
Time frame: Up to 14 months
Accrual rate
To be determined by comparing monthly actual versus (vs.) projected rate of recruitment for the trial disease groups (i.e., non-small cell lung cancer, colon cancer, breast cancer, prostate cancer, kidney cancer, lymphoma) using generalized estimating equations, accounting for intra-disease random effects and trends across the 12 months (9 months exposure per trial). These results will then be put into context of the historic recruitment for these diseases at the center.
Time frame: Up to 14 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.